Capital Markets Day & technology agreement
LiDCO Group Plc
("LiDCO" or the "Company")
Capital Markets Day & updated non-invasive technology agreement
LiDCO (AIM: LID), the hemodynamic monitoring company, is hosting a Capital Markets Day for investors today at FinnCap's offices at 60 New Broad Street, London, EC2M 1JJ. The presentations will be available later today on the Company's website http://www.lidco.com/investors/presentations/. Except as set out below, no new material price sensitive information will be provided.
Today, LiDCO announces that the Company has signed a variation agreement to its existing commercial collaboration with CNSystems Medizintechnik AG, Graz, Austria ("CNS") providing LiDCO with access to CNS' latest continuous non-invasive blood pressure monitoring ('CNAP') software.
The main improvements with this latest software are:
- Faster set-up, significantly reducing the time to start monitoring, meaning that clinicians can be monitoring their patients in less than a minute
- Sensor size assistant, automatically recognising if an incorrect sensor size is attached, ensuring an error-free application that gives notice to the user if finger sensor size does not fit
- Improved signal optimisation, for more reliable short and long term blood pressure tracking, featuring a new automated signal quality check that analyses blood pressure on a beat-to-beat basis to ensure better tracking of quick blood pressure changes
These significant upgrades are part of the continuous development and life cycle management of LiDCO's technology. The Company expects to launch these as part of its existing monitor platform in the first half of 2020.
Commenting, Matt Sassone, Chief Executive Officer of LiDCO, said: "CNS is an important partner for LiDCO and these new improvements provide us with exciting features that we can offer to new and existing customers. Our non-invasive technology is an important part of our HUP offering which will be further strengthened by these innovations."
For further information, please contact:
LiDCO Group Plc
Matt Sassone (CEO)
Tel: +44 (0)20 7749 1500
Tim Hall (CFO)
| || |
Tel: +44 (0)20 7600 1658
Geoff Nash / Hannah Boros (Corporate Finance)
Andrew Burdis (Corporate Broking)
| || |
Walbrook PR Ltd
Tel: 020 7933 8780 or [email protected]
Mob: 07980 541 893
Mob: 07584 391 303
About LiDCO Group Plc (www.lidco.com)
LiDCO is a supplier of non-invasive and minimally invasive hemodynamic equipment to hospitals used to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the application of hemodynamic optimisation protocols for high risk patients in both critical care units and in the operating theatre.
Increasingly clinical studies are showing that the optimisation of patients' hemodynamic status in high risk patients produces better outcomes and reduced hospital stay. LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.
LiDCOunity: a hemodynamic monitor that combines the full suite of LiDCO technology (non-invasive, minimally invasive and calibrated technologies) into one platform. Designed to have the flexibility to adapt to a patient's changing acuity, the product enables clinicians to seamlessly transition between non-invasive, minimally invasive and calibrated hemodynamic monitoring.
LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%).
LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anaesthetists to receive accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery. The LiDCOrapid provides:
· early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug
· quantification of hemodynamic response guidance on effective delivery of fluids to ensure the right amount at the right time
The software incorporated into LiDCOrapid allows the LiDCOrapid monitor to co-display Medtronic's level of consciousness parameter ('BISTM')* and add the convenience of CNSystem's continuous non-invasive blood pressure monitoring ('CNAP')**. This addresses a growing requirement for non-invasive monitoring solutions that are more comprehensive and can effectively replace multiple single parameter monitors.
LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
*BISTM and Bispectral Index are trademarks of Medtronic registered in the US and foreign countries.
**CNAPTM is a trademark of CNSystems Medizintechnik AG.
LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream.
LiDCO Distribution Network:
LiDCO sells directly to hospitals in the UK and USA and through a network of specialty critical care and anaesthesia distributors in the rest of the world.
LiDCO's headquarters are in London and its shares are traded on AIM.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
Quick facts: LiDCO Group PLC
Market Cap: £11.6 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE